Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,200 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07129642RecruitingEarly Phase 1
Donor CAR-T cells for hard-to-treat Graves' disease
This trial tests a new type of cell therapy called CAR-T cells made from a donor. The cells target B cells that may drive Graves' disease. It's for people whose Graves' disease has not gotten better with usual treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07130903RecruitingPhase 2
Fruquintinib plus special radio waves for advanced colon cancer
This trial tests whether combining fruquintinib (a pill) with low-level radio waves can help people whose metastatic colorectal cancer has stopped responding to or is intolerant of standard treatments. It’s for those who have tried certain chemotherapies and anti-VEGF therapy.
Bay City, MichiganAges 22 years+ - NCT07126431Recruiting
Study of hard-to-treat rheumatoid arthritis
This study is observing people with a hard-to-treat form of rheumatoid arthritis (RA). Researchers want to understand what treatments and outcomes are like for people whose RA doesn't get better with standard medications like methotrexate.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07125872RecruitingPhase 2
New drug for relapsed B-cell lymphoma
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
JohannesburgAges 18 years+ - NCT07121946RecruitingPhase 1
Safety study of LTZ-301 for non-Hodgkin lymphoma
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Duarte, CaliforniaAges 18 years+ - NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT07124390Recruiting
Electroacupuncture for stubborn overactive bladder
This study tests whether electroacupuncture (a type of acupuncture with mild electrical stimulation) can help women whose overactive bladder symptoms have not responded to usual treatments. If you join, you will receive electroacupuncture sessions and be monitored to see if your symptoms improve.
London, United KingdomAges 18 years+ - NCT04722029RecruitingPhase 1/Phase 2
Donor immune-cell therapy for stubborn adenovirus infections
This study tests whether specially matched donor T-cells can control “refractory” adenovirus (a virus) that isn’t responding to usual antiviral medicines. It may help if the infection keeps coming back or is already affecting organs like the lungs or bowel.
Columbus, OhioAges Up to 60 years - NCT07110337Recruiting
Diagnosing epilepsy to help guide treatment
This trial tests a new device to help diagnose epilepsy in people whose previous EEG brain monitoring did not give clear answers. If you have drug-resistant epilepsy with at least one seizure a month on average, this study may help find better treatment options.
Birmingham, AlabamaAges 18–75 - NCT07109986RecruitingPhase 1
Study of UB-VV410 for active lupus or lupus nephritis
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
NanjingAges 18–65 - NCT07113665RecruitingPhase 1
Focused ultrasound brain treatment for severe anorexia
This trial tests if focused ultrasound can help people with severe anorexia nervosa who also have obsessive-compulsive disorder or major depression. It is for those who have not gotten better with other treatments.
Toronto, OntarioAges 18–65 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07108257Recruiting
Focused ultrasound for bipolar depression
This trial uses sound waves guided by MRI to target a small brain area. It aims to help people with bipolar depression that hasn't improved with standard treatments.
Toronto, OntarioAges 18–65 - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106827RecruitingPhase 1
Study of a new drug for advanced or resistant solid tumors
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
Chengdu, SichuanAges 18 years+ - NCT07096934RecruitingPhase 1/Phase 2
Testing a new cell treatment for stubborn diabetic foot ulcers
This trial tests a new treatment using special skin cells grown into tiny spheres (spheroids) to help heal diabetic foot ulcers that have not healed with standard care. It aims to see if this treatment is safe and works better than usual care.
Coffs Harbour, New South WalesAges 18–80 - NCT07095933RecruitingEarly Phase 1
Everolimus for hard-to-control focal epilepsy
This study tests whether the medicine everolimus (taken as a pill) can safely reduce seizures in adults with focal epilepsy that hasn't been controlled by other treatments. You would continue your current seizure medicines and add everolimus.
Beijing, Beijing MunicipalityAges 18–60 - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06971380RecruitingPhase 2
CAR-T therapy for multiple myeloma and amyloidosis
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
JerusalemAges 18 years+ - NCT06859164RecruitingPhase 2
Knee artery treatment for chronic osteoarthritis pain
This trial tests a procedure called genicular artery embolization to reduce pain in people with knee osteoarthritis that hasn't improved with other treatments. The goal is to see if blocking certain blood vessels can relieve pain and help you avoid or delay knee replacement surgery.
Chicago, IllinoisAges 40–80 - NCT07086404RecruitingEarly Phase 1
GC012F injection for stubborn inflammatory muscle disease
This trial tests a new cell therapy (GC012F) for people with idiopathic inflammatory myopathy (IIM) that hasn't responded to standard treatments. It aims to see if this treatment can help control muscle inflammation and weakness.
Wuhan, HubeiAges 18–70 - NCT07093710RecruitingPhase 1/Phase 2
Golidocitinib combo for relapsed peripheral T-cell lymphoma
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
Guangzhou, GuangdongAges 18 years+ - NCT07094048RecruitingPhase 4
Immunoglobulins for multiple myeloma patients on BCMA T-cell engagers
This trial tests whether giving immunoglobulins (a treatment to boost your immune system) helps multiple myeloma patients who are receiving a BCMA-directed T-cell engager therapy. It aims to see if this can reduce infections and improve outcomes.
Lévis, QuebecAges 18 years+
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,200 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.